Enliven
enlivenempathy.com
Business Development
Transportation & Logistics
Consumer Goods
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Read more
Report
- Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.
This oncology-focused biotech, advancing kinase inhibitors for cancer, reported a notable insider sale amid strong one-year stock gains.
Read more
Report
Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho
Enliven Therapeutics, Inc. (NASDAQ:ELVN) is one of the 10 Best Performing Stocks of Q1 2026 to Watch for Q2. On March 26, H.C. Wainwright increased its price target on Enliven Therapeutics, Inc. (NASDAQ:ELVN) from $48 to $56 and kept its Buy rating on the
Read more
Report
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
/PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
Read more
Report
Report
Cancer drug biotech Enliven shifts to reverse to move forward as a public company
Enliven Therapeutics' reverse merger with Imara will form a combined company with $300 million to finance clinical development of new cancer drugs. Its most advanced program is a tyrosine kinase inhibitor for chronic myeloid leukemia.
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Arnhem
Netherlands
Regional office
General Terms and Conditions 2026
10-50 est. staff
Registered office: Jansbuitensingel 30, 6811AE Arnhem, the Netherlands